The last two pharmaceutical companies that received approval from the FDA (before the pandemic) to produce new antibiotics - one went bankrupt and the other got sold off. There is little financial incentive to research or produce these drugs. Researcher Lori Burrows talks to us about new supply models that could re-ignite research in this area.

Globally, we are quickly running out of antibiotic solutions to fight both common and high-risk bacterial infections. Bacteria are becoming increasingly resistant to over-used antibiotics, and it
is no longer financially viable for pharmaceutical companies to invest in the research and development of new antibiotics. The WHO and UN have prioritized this problem. What does this mean for vulnerable patients, and can prevention help?

The phone call no parent ever wants to receive… Hear how Seana and her husband went through the harrowing first 14 months of her daughter Kiera’s illness before receiving a proper diagnosis, her 18-month stay in hospital and all the care, logistics and education that come with living with a child who requires an IV catheter connected to her heart, and how one solution is
helping these parents reduce their fears that their child’s lifeline could be deadly.

A caregiver by nature and registered nurse by training, SterileCare CEO Karen Mueller explains
why solution-driven healthcare, as opposed to our current fear-driven healthcare, along with a
dash of good business sense, is the right path forward to a more effective system. This
approached helped her see that a solution eradicating the formation and growth of IV line
bacteria and blockages was the right tool to help save not only patients’ lives, but precious
healthcare resources.

In Canada, 34 people die every single day from PREVENTABLE bloodstream infections acquired
in hospitals. Why? Because bacteria are about to outsmart antibiotics due to overuse and
decline in production. Hear from a patient, a researcher and the CEO of a Canadian-made
solution about the danger of bacterial resistance to antibiotics for populations and what can be
done to tackle this issue.